Screener
BioLife Solutions BLFS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by BioLife Solutions in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: BioLife Solutions’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:22 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054355
FAQ
- What is BioLife Solutions's cash & equivalents?
- BioLife Solutions (BLFS) reported cash & equivalents of $24M in Q2 2026.
- How has BioLife Solutions's cash & equivalents changed year-over-year?
- BioLife Solutions's cash & equivalents decreased by 24.8% year-over-year, from $31.9M to $24M.
- What is the long-term trend for BioLife Solutions's cash & equivalents?
- Over 5 years (2020 to 2025), BioLife Solutions's cash & equivalents has grown at a -18.2% compound annual growth rate (CAGR), from $90.4M to $33.04M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about BioLife Solutions's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude